Evolus, Inc. (NASDAQ:EOLS) CFO Sells $17,208.10 in Stock

Evolus, Inc. (NASDAQ:EOLS) CFO Sandra Beaver sold 1,586 shares of the business’s stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $10.85, for a total transaction of $17,208.10. Following the transaction, the chief financial officer now owns 146,916 shares in the company, valued at $1,594,038.60. This represents a 1.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Evolus Trading Down 2.3 %

Shares of EOLS stock opened at $11.09 on Friday. Evolus, Inc. has a 12-month low of $9.80 and a 12-month high of $17.82. The company has a market capitalization of $702.23 million, a PE ratio of -12.19 and a beta of 1.27. The firm has a 50 day moving average price of $13.35 and a two-hundred day moving average price of $13.73. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Barclays boosted their price target on Evolus from $16.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th. Cantor Fitzgerald reissued an “overweight” rating on shares of Evolus in a report on Monday, September 16th. HC Wainwright restated a “buy” rating and issued a $27.00 price target on shares of Evolus in a research note on Thursday, November 7th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price objective on shares of Evolus in a research report on Friday, September 13th.

Institutional Trading of Evolus

Several hedge funds have recently added to or reduced their stakes in EOLS. Armistice Capital LLC acquired a new position in Evolus in the 2nd quarter valued at $3,906,000. Charles Schwab Investment Management Inc. boosted its position in shares of Evolus by 173.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 418,576 shares of the company’s stock valued at $6,781,000 after acquiring an additional 265,635 shares during the period. Ikarian Capital LLC acquired a new position in shares of Evolus in the third quarter valued at about $4,184,000. Walleye Capital LLC bought a new position in Evolus during the third quarter worth about $3,438,000. Finally, Lord Abbett & CO. LLC raised its stake in Evolus by 23.4% in the 3rd quarter. Lord Abbett & CO. LLC now owns 995,449 shares of the company’s stock worth $16,126,000 after purchasing an additional 188,685 shares in the last quarter. 90.69% of the stock is owned by institutional investors and hedge funds.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.